公开(公告)号：US10463626B2

公开(公告)日：2019-11-05

申请号：US15556913

申请日：2016-03-11

Applicant: UNIVERSITY OF SOUTH AUSTRALIA

Inventor： Clive Allan Prestidge ,  Paul Matthew Joyce

IPC: A61K9/50 ,  A61K31/495

Abstract: A dry composition, comprising three-dimensional porous microparticles, wherein the microparticles comprise: (i) an active substance (eg a poorly water soluble drug), (ii) polymeric nanoparticles such as those composed of a biocompatible and/or biodegradable polymer (eg a PLGA polymer) (iii) lipid droplets (eg droplets of a medium chain triglyceride (MCT)), (iv) a nanoparticle stabilizing agent such as PVA or DMAB, and optionally, (v) a cryoprotectant (eg mannitol); wherein said active substance is carried by said nanoparticles and/or lipid droplets. The composition of the present invention may be formulated into, for example, a medicament for the treatment and/or prevention of various diseases or disorders (eg human or veterinary therapeutics). The average diameter of the individual microparticles of the composition, may be in the order of 2.5-3.5 μm which are particularly suitable for administration to the lung.

公开(公告)号：US20170165199A1

公开(公告)日：2017-06-15

申请号：US15277177

申请日：2016-09-27

Applicant: University of South Australia

Inventor： Clive Allan Prestidge ,  Spomenka SIMOVIC

IPC: A61K9/127 ,  A61K38/00 ,  A61K8/06 ,  A61K8/25 ,  A61K8/55 ,  A61K8/63 ,  A61K47/02 ,  A61K47/24 ,  A61K47/28 ,  A61Q17/04 ,  A61K9/10 ,  A61K8/04 ,  A23L33/115 ,  A23P10/35 ,  A61K31/7088

CPC classification number: A61K9/1271 ,  A23L33/115 ,  A23P10/35 ,  A23V2002/00 ,  A61J3/005 ,  A61J3/02 ,  A61K8/0241 ,  A61K8/04 ,  A61K8/06 ,  A61K8/11 ,  A61K8/25 ,  A61K8/553 ,  A61K8/63 ,  A61K9/10 ,  A61K9/1075 ,  A61K9/127 ,  A61K9/14 ,  A61K9/501 ,  A61K9/5089 ,  A61K9/5115 ,  A61K9/5192 ,  A61K31/7088 ,  A61K38/00 ,  A61K47/02 ,  A61K47/24 ,  A61K47/28 ,  A61K2800/412 ,  A61K2800/413 ,  A61K2800/651 ,  A61Q17/04 ,  A61Q19/00 ,  B01J13/02 ,  B01J13/22 ,  B82Y5/00

Abstract: A method of producing a dried formulation for an active substance such as a drug compound is described. The method involves dispersing a discontinuous phase (e.g. an oil-based or lipidic medium) comprising the active substance into a continuous phase (e.g. water) so as to form a two-phase liquid system comprising droplets of said discontinuous phase, allowing nanoparticles to congregate at the phase interface at the surface of the droplets such that at least one layer of nanoparticles coat the droplets and thereby provide sufficient structural integrity to the droplets to enable the subsequent removal of the continuous phase, and thereafter removing the continuous phase from the nanoparticle-coated droplets to produce a dried formulation.